Phase 2 Lung Cancer Trial, Recruiting NCT06496490 Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Recruiting

NCT06496490
Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have agreed to take part voluntarily and have signed a consent form
  • People aged between 18 and 75 years old at the time of signing the consent form
  • People with a good general activity level, rated 0 or 1 on a standard performance scale (confirm with trial site), and an expected survival of at least 3 months
  • People who have been diagnosed with locally advanced, spreading, or returning non-small cell lung cancer that has been confirmed by laboratory testing of cells or tissue, and where surgery or combined chemotherapy and radiotherapy aimed at a cure are not options
  • People whose previous standard cancer treatments have stopped working
  • People who have at least one measurable area of cancer that can be tracked using standard imaging criteria
  • Women of childbearing age who agree to use contraception during the study and for 6 months after it ends, have a negative blood pregnancy test within 7 days before joining, and are not currently breastfeeding
  • Men who agree to use contraception during the study and for 6 months after it ends

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have been diagnosed with or treated for another cancer within the past 3 years
  • People who still have side effects from previous treatments that have not settled back to a mild level or below (with the exception of hair loss)
  • People who had major surgery, a large biopsy, or a significant injury within 28 days before starting the study, or a minor procedure such as a small biopsy, bronchoscopy, or chest drain within 7 days before starting
  • People with wounds or bone fractures that have not healed over a long period of time
  • People with a history of certain lung conditions, including interstitial lung disease, radiation-related lung inflammation, or immune-related lung inflammation that required steroid treatment, or who currently have active forms of these conditions, active tuberculosis, dust-related lung disease, other lung inflammation of grade 2 or higher, or severely reduced lung function confirmed by breathing tests
  • People who have had a blood clot event — such as a stroke, deep vein thrombosis, or pulmonary embolism — within the 6 months before treatment
  • People with a history of substance abuse who are unable to stop, or people with a diagnosed mental health disorder
  • People with any severe or uncontrolled illness
  • People who have received any cancer treatment or participated in another drug trial within 28 days, or within 5 half-lives of that drug, before the first dose in this study
  • People who received certain Chinese traditional patent medicines with approved anti-tumour indications within 1 week before the first dose (confirm with trial site)
  • People who received localised palliative radiotherapy within 2 weeks before the first dose
  • People who have fluid build-up in body cavities that requires repeated draining to manage symptoms, or who had such fluid drained for treatment purposes within 2 weeks before starting
  • People whose cancer has spread to the brain or the lining around the brain and is currently causing symptoms or getting worse — although people with a history of stable brain metastases may be considered (confirm with trial site)
  • People who have had, or are at high risk of, serious bone damage from cancer spreading to the bones, including broken bones or spinal cord compression within the past 6 months
  • People with bone pain from cancer spread to the bones that is not well controlled
  • People who have a known allergy to humanised monoclonal antibody medicines (a type of targeted therapy)
  • People who are allergic to any of the study drugs or their ingredients
  • People who have received a live attenuated vaccine within 4 weeks before treatment
  • People who, in the treating doctor's judgement, have other conditions that could put them at serious risk or affect the study's completion, or who are considered unsuitable for other reasons

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 31 July 2026

If this is close to home

This page includes language about advanced illness, prognosis, or palliative care, because that is how the trial's eligibility criteria are written. Seeing it set out plainly can land hard, whether it is about you or about someone you are caring for. You do not have to be at a crisis point to talk to someone.

  • Griefline — grief and loss counselling, 9am to 6pm weekdays and midday to 6pm weekends (AEST/AEDT): 1300 845 745
  • Carer Gateway — practical and emotional support if you are caring for someone, 8am to 5pm weekdays: 1800 422 737
  • Canteen — for 12 to 25 year olds affected by cancer, their own or a family member's: 1800 945 215
  • Palliative Care Australia — directory of palliative care services near you: palliativecare.org.au
  • Lifeline — 24/7, for any kind of distress, at any hour the services above are closed: 13 11 14

Palliative care is not the same as giving up on treatment, and it is not only for the last weeks of life. It is symptom and comfort care that can run alongside active treatment, including a clinical trial.

Outside Australia? The numbers above are Australian and will not work from overseas. Find a Helpline is a free directory of support and crisis lines in over 130 countries, run by ThroughLine with the International Association for Suicide Prevention.

Voxsanity is not a counselling or medical service, and nothing on this page is medical advice. More Australian services are listed on our support lines page.

Contact this trial

Phone: 020-87343458

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Registry
ClinicalTrials.gov
Start date
6 August 2024
Est. completion
1 June 2026

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Overall Response Rate (ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov